Selected article for: "develop antiviral and high morbidity"
Author: Glowacka, Ilona; Bertram, Stephanie; Pöhlmann, Stefan
Title: Cellular Entry of the SARS Coronavirus: Implications for Transmission, Pathogenicity and Antiviral Strategies
  • Cord-id: qnij7u1h
  • Document date: 2009_7_22
    • ID: qnij7u1h
    Snippet: A novel coronavirus was identified as the causative agent of the lung disease severe acute respiratory syndrome (SARS). The outbreak of SARS in 2002/2003 was associated with high morbidity and mortality and sparked international research efforts to develop antiviral strategies. Many of these efforts focussed on the viral surface protein spike (S), which facilitates the first indispensable step in the viral replication cycle, infectious entry into target cells. For infectious cellular entry to oc
    Document: A novel coronavirus was identified as the causative agent of the lung disease severe acute respiratory syndrome (SARS). The outbreak of SARS in 2002/2003 was associated with high morbidity and mortality and sparked international research efforts to develop antiviral strategies. Many of these efforts focussed on the viral surface protein spike (S), which facilitates the first indispensable step in the viral replication cycle, infectious entry into target cells. For infectious cellular entry to occur, the S protein must engage a cellular receptor, the carboxypeptidase angiotensin-converting enzyme 2 (ACE2). The interface between ACE2 and S protein, which has been characterized at the structural level, constitutes a key target for vaccines and inhibitors, and is believed to be an important determinant of viral pathogenesis and interspecies transmission. In this chapter, we will discuss how SARS-S mediates cellular entry and we will review the implications of this process for SARS coronavirus (SARS-CoV) transmission, disease development and antiviral intervention.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and adam metallopeptidase domain: 1
    • acute ards respiratory distress syndrome and low efficiency: 1, 2
    • acute ards respiratory distress syndrome and lung detect: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and lung epithelium: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute ards respiratory distress syndrome and lung failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome development and lung epithelium: 1, 2
    • acute ards respiratory distress syndrome development and lung failure: 1, 2, 3
    • acute lung failure and lung failure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • adam metallopeptidase and lung epithelium: 1
    • adam metallopeptidase domain and lung epithelium: 1